7436-22-8

Basic information

• Product Name: METHYL-D3-AMINE HYDROCHLORIDE
• Synonyms: METHYL-D3-AMINE HCL;METHYL-D3-AMINE HYDROCHLORIDE;METHYL-D3-AMMONIUM CHLORIDE;METHYLAMINE-D3 HYDROCHLORIDE;(2H3)methylammonium chloride;METHYL-D3-AMINE HYDROCHLORIDE, 99 ATOM % D;Methyl-D3-amineCl;Methan-d3-amine hydrochloride
• CAS NO: 7436-22-8
• Molecular Formula: CH₆N*Cl
• Molecular Weight: 70.54
• EINECS: 231-089-6
• Product Categories: Aliphatics;Amines;Isotope Labelled Compounds
• Mol File: 7436-22-8.mol

Chemical Properties

• Melting Point: 232-234 °C(lit.)
• Appearance: /
• Vapor Pressure: 3970mmHg at 25°C
• CAS DataBase Reference: METHYL-D3-AMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-D3-AMINE HYDROCHLORIDE(7436-22-8)
• EPA Substance Registry System: METHYL-D3-AMINE HYDROCHLORIDE(7436-22-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 7436-22-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL-D3-AMINE HYDROCHLORIDE is used as a precursor in the synthesis of deuterated diphenylurea derivatives for their potential as phosphokinase inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer and other disorders characterized by abnormal cell signaling and energy metabolism.
In the field of medicinal chemistry, the incorporation of deuterium into drug molecules can lead to improved pharmacokinetic and pharmacodynamic properties, such as enhanced stability, reduced metabolism, and increased bioavailability. This makes METHYL-D3-AMINE HYDROCHLORIDE a valuable building block for the design and development of novel therapeutic agents with optimized performance.

InChI:InChI=1/CH5N.ClH/c1-2;/h2H2,1H3;1H/i1D3;

Upstream product

• 85894-44-6 N-Nitroso-N-methyl-d₃-methoxymethylamine 
• 1221168-47-3 (N-(methyl-d3))-isoindole-1,3-dione instead of 2-(N-(methyl-d3))-isoindole-1,3-dione 
• 13031-32-8 nitromethane-d3 
• 593-51-1 methylamine hydrochloride 
• 122025-10-9 C₈H₈⁽²⁾H₃N*ClH 

Downstream Products

• 3669-71-4 N-(methyl-d3)acetamide 
• 65100-49-4 5-[3-(N-trideuteromethylamino)propyl]iminodibenzyl 
• 1189858-48-7 4-chloropyridinyl-2-(N-1',1',1'-trideuteromethylcarboxamide) 
• 1609392-27-9 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d₃)pyridazine-3-carboxamide 
• 144601-75-2 N-trideuteriomethyl-benzamide 
• 1126623-89-9 C₂₂H₁₅⁽²⁾H₃N₄OS 
• 1443331-82-5 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-trideuteriomethylbenzamide 

Relevant articles and documents

A Small Lattice Change Induces Significant Dynamic Changes of CH3NH3+ Caged in Hybrid Perovskite Crystals: Toward Understanding the Interplay between Host Lattices and Guest Molecules

Two perovskite-type compounds, (MA)2[B′Co(CN)6] (MA = methylammonium, B′ = K(I) and Na(I)), have very similar structures, but exhibit marked differences in the phase and dielectric transitions. Solid state 2H NMR studies reveal the detailed dynamic changes of the caged methylammonium (MA) cations before and after the phase transitions, which are correlated with the different dielectric states of the compounds. Using solid state 59Co NMR, the dynamic changes of the host lattices before and after the transitions, which accompany the changes in the dynamics of the caged MA cations, are unveiled, demonstrating the intriguing interplay between the MA cations and the host lattices. On the basis of these observations, the molecular origins of the dielectric transitions are discussed in detail.

Method for preparing deuterated methylamine salt through photocatalysis

The invention discloses a method for preparing deuterated methylamine salt through photocatalysis, and relates to the technical field of deuterated synthesis. The method for preparing the deuterated methylamine salt through photocatalysis comprises the following steps: S1, reacting a benzylamine compound with deuterated methanol under the action of a semiconductor photocatalyst at room temperature to obtain an N-deuterated methyl benzylamine compound; and S2, carrying out catalytic hydrogenation debenzylation on the N-deuterium methyl benzylamine compound in a hydrogen atmosphere under the action of a solvent, acid and a catalyst to obtain the deuterated methylamine salt. According to the method provided by the invention, cheap deuterated methanol is used as a deuterium source, the semiconductor photocatalyst is used for catalyzing deuteration, the reaction condition is mild, the yield is high, the deuteration rate can reach 100%, the operation is simple and convenient, and the cost is low; the deuterated methylamine or deuterated dimethylamine hydrochloride can be conveniently and quickly regulated and synthesized by controlling the number of benzyl groups; the synthesized product deuterated methylamine salt can be used as a deuterated building block to be widely applied to synthesis of deuterated drugs, so that the synthesis cost of the deuterated drugs is further reduced, and the deuterated methylamine salt has industrial value.

Method for synthesizing deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride from benzylamine protected by Boc

The invention discloses a method for synthesizing deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride by using Boc-protected benzylamine. The method mainly comprises the following step: reacting Boc-protected benzylamine serving as a raw material with a deuteration methylation reagent under alkaline conditions to generate deuterated methylamine hydrochloride and deuterated dimethylamine hydrochloride. The synthesis method provided by the invention can avoid the disadvantage that trisubstituted and tetrasubstituted methyl byproducts are easy to generate in the conventional synthesis method. Therefore, the method for preparing the deuterated methylamine hydrochloride and the deuterated dimethylamine hydrochloride has the advantages of few byproducts and easiness in purification, and has important guidance value for research and development and synthesis of deuterated drugs.

A practical synthesis of deuterated methylamine and dimethylamine

In recent years, several deuterated drugs have entered clinical trials and have been approved for use. Deuterated methylamine and dimethylamine as important intermediates play significant roles in the preparation of deuterated drugs. In this study, we have developed a new method to prepare deuterated methylamine and dimethylamine. This method employs Boc-benzylamine as the starting material and TsOCD3 as the deuterated methylation reagent. Our method gives relatively high yields and involves simple purifications, which provide a favourable supplement for the development and synthesis of deuterated drugs in the future.

Deuterated compound and application thereof in treatment of cancer

The present invention relates to a deuterated compound and application thereof in the treatment of cancer. Specifically, the present invention provides the compound of formula (I) and pharmaceuticallyacceptable salt or ester thereof, and a pharmaceutical composition thereof. The compound and the pharmaceutical composition are used for inhibiting or regulating the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

Method for synthesizing deuterated methylamine salt by using halogenated deuterated methane

The invention discloses a method for synthesizing deuterated methylamine and a deuterated methylamine salt by using halogenated deuterated methane. The method comprises the following steps: (1) carrying out a reaction on a compound 1 with R-NH2 in the presence of a strong alkali and/or an inert solvent to obtain a compound 2; and (2) carrying out a reaction on the compound 2 with an acid, so as toobtain the deuterated methylamine salt. The preparation method provided by the invention has simple preparation method, high efficiency and low cost, and has a good industrial application prospect.

CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE

Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.

PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Preparation deuterated diphenylurea (by machine translation)

The invention relates to a method for preparing deuterated diphenyl urea. Specifically, the invention provides an intermediate N-(1, 1, 1-3 deuterated methyl) benzo succinimide which can be used for preparing a deuterated diphenyl urea compound and an application of the intermediate in the preparation of the deuterated diphenyl urea compound. The method can be used for conveniently preparing the intermediate with the high purity and various deuterated diphenyl urea compounds in high efficiency.

PYRIMIDINE OR PYRIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF

The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).